Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract

BMJ Case Reports

Volumn , Issue , 2011, Pages

  Mejhert, Marit ^a   Hast, Robert ^b   Sandstedt, Benngt ^a   Janczewska, Izabella ^c  

^a DANDERYD HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETAMETHASONE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIURETIC AGENT; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN LIGHT CHAIN; OMEPRAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIUM DETECTION; CASE REPORT; CLINICAL FEATURE; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; ELECTROCARDIOGRAM; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; GASTROSCOPY; HEART AMYLOIDOSIS; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HELICOBACTER PYLORI; HUMAN; MELENA; PRIORITY JOURNAL; STOMACH ULCER; THORAX PAIN; ULCERATIVE COLITIS;

EID: 80053070815     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr.03.2011.4007     Document Type: Article

References (31)

1. Bellotti V, Merlini G. Current concepts on the pathogenesis of systemic amyloidosis. Nephrol Dial Transplant 1996;11(Suppl 9):53-62. (Pubitemid 27076020)
2. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59. (Pubitemid 24370135)
3. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992;79:1817-22.
4. Perz JB, Rahemtulla A, Giles C, et al. Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2006;37:937-43. (Pubitemid 43792554)
5. Kristen AV, Perz JB, Schonland SO, et al. Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis. J Heart Lung Transplant 2007;26:1313-19. (Pubitemid 350256989)
6. Moreau P, Milpied N, De Faucal P, et al. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement. Blood 1996;87:3063-4. (Pubitemid 26102262)
7. Comenzo RL, Vosburgh E, Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 1996;88:2801-6. (Pubitemid 26327537)
8. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 1998;101:766-9. (Pubitemid 28308529)
9. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid lightchain) amyloidosis: survival and responses in 25 patients. Blood 1998;91:3662-70. (Pubitemid 28225733)
10. Casserly LF, Fadia A, Sanchorawala V, et al. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int 2003;63:1051-7. (Pubitemid 36315584)
11. Gono T, Matsuda M, Dohi N, et al. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med 2003;42:72-7. (Pubitemid 36267669)
12. Worel N, Schulenburg A, Mitterbauer M, et al. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity. Wien Klin Wochenschr 2006;118:49-53. (Pubitemid 43356459)
13. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85-93.
14. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002;99:4276-82. (Pubitemid 34627192)
15. Sanchorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid 2007;14:261-9. (Pubitemid 350035577)
16. Palladini G, Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr Opin Oncol 2011;23:214-20.
17. Dietrich S, Schönland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010;116:522-8.
18. Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 2010;116:4777-82.
19. Dispenzieri A, Lacy MQ, Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007;109:465-70. (Pubitemid 46105939)
20. Sanchorawala V, Wright DG, Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007;109:492-6. (Pubitemid 46105943)
21. Lamm W, Willenbacher W, Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 2011;90:201-6.
22. Kastritis E, Wechalekar AD, Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28:1031-7.
23. Kastritis E, Anagnostopoulos A, Roussou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007;92:1351-8. (Pubitemid 350144152)
24. Janczewska I, Mejhert M, Hast R, et al. Primary AL-amyloidosis, ulcerative colitis and collagenous colitis in a 57-year-old woman: a case study. Scand J Gastroenterol 2004;39:1306-9. (Pubitemid 39656850)
25. Gertz MA, Lacy MQ, Gastineau DA, et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 2000;26:963-9.
26. Dispenzieri A, Kyle RA, Lacy MQ, et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004;103:3960-3. (Pubitemid 38596319)
27. Sanchorawala V, Skinner M, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007;110:3561-3. (Pubitemid 350159622)
28. Blair JE, Zeigler SM, Mehta J, et al. Regression of cardiac amyloid after autologous stem-cell transplantation. J Heart Lung Transplant 2009;28:746-8.
29. Van Gameren II, Hazenberg BP, Jager PL, et al. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid 2002;9:165-74. (Pubitemid 35205206)
30. Sanchorawala V, Wright DG, Seldin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001;28:637-42. (Pubitemid 33014596)
31. Yagi S, Akaike M, Ozaki S, et al. Improvement of cardiac diastolic function and prognosis after autologous peripheral blood stem cell transplantation in AL cardiac amyloidosis. Intern Med 2007;46:1705-10. (Pubitemid 350111142)